022 82 44 44

Ultra-personalized treatment
For refractory and metastatic cancer

Treatment-resistant (refractory) and metastatic forms of cancer present a significant clinical challenge due to the limited availability of effective treatment options and an inevitably unfavorable prognosis. These patients require well-designed strategies for selecting personalized treatment regimens that consider both the molecular and functional dynamics of the tumor. Such strategies aim to target the tumor's vulnerabilities effectively while proactively addressing known mechanisms of resistance.
Combining anticancer drug regimens can have a synergistic effect, preventing malignant “escape” mechanisms and reducing drug resistance rates. This approach leads to more effective treatment, lowers the risks of ineffective therapy, and reduces its associated toxicity.

Exacta – a minimally invasive diagnostic test designed for multi-analytical profiling of tumor genomes, with simultaneous in-vitro assessment of chemosensitivity on living tumor cells, aiming to identify all potential targets for prescribing drugs to achieve best clinical outcomes
Based on a safe blood test (if necessary, on tumor tissue analysis

Exacta is a multi-analytical and multi-dimensional study of the tumor interactome, designed to identify the most effective drugs for each specific type of cancer and to develop complex ultra-personalized treatment strategies, including for metastatic and refractory (resistant) forms. The recommended treatment does not depend on the primary organ of origin, histological type/subtype, morphology (grade of malignancy), or aggressiveness of the tumor. Instead, it is based solely on compelling evidence of drug efficacy for the specific tumor of the individual patient. Drugs with the highest potential for clinical success are selected through in-vitro testing on live tumor cells and taking into account the evolution of the cancer. This approach eliminates any "experiments" on the patient's body, reducing unnecessary toxicity and saving precious time by avoiding ineffective treatments.

For professional use only
Developed, validated and certified by Datar Cancer Genetics

Opportunities

Optimal Cytotoxic Therapy
Determination of chemosensitivity in vitro on live tumor cells. Evaluation of response/resistance to cytotoxic drugs based on DNA analysis and gene expression
Optimal Targeted Therapy
Identification of the most vulnerable molecular targets of the tumor through comprehensive molecular analysis of all relevant biomarkers (mutations, deletions, rearrangements, amplifications, and gene expression). Additional analysis of the impact of simultaneous molecular markers of resistance and sensitivity.
Optimal Immunotherapy
Analysis of clinical biomarkers such as PD-L1, tumor mutational burden, and microsatellite instability
Drug Toxicity/Adverse Drug Reactions
Prediction of adverse drug reactions/toxicity based on the analysis of genetic polymorphisms of drug-metabolizing enzymes
Drug Repurposing
Analysis of additional therapeutic options for recurrent or progressing high-grade cancers, despite prior treatment

Methodology

Exacta evaluates:

Key elements and characteristics of the molecular and functional interactome that support and drive cancer progression, such as molecular perturbations and their dynamics
Functional chemosensitivity/resistance which are a consequence of overall molecular dynamics

Target genes
Single Nucleotide Variations (SNV), Copy Number Variations (CNV), Insertions and Deletions (Indels), Mutational Burden, Germline Mutations
RNA sequencing
KEGG pathways associated with disease, therapeutic and resistance patterns
Pharmacogenetics
Genotyping of CYP450, transporter proteins for assessment of drug efficacy and toxicity
Chemosensitivity
In vitro analysis on living tumor cells for evaluation of cytotoxic drugs
Immunocytochemistry
Analysis of expression of therapeutically significant protein markers (mTOR, VEGFR1, VEGFR2, VEGFA, EGFR)
Liquid Biopsy
Mutational burden, tumor heterogeneity

Clinically proven efficacy

High clinical efficacy has been convincingly demonstrated in the RESILIENT study/protocol (CTRI/2018/02/011808). The RESILIENT protocol is the world's first and only prospective Precision Oncology study in which drug combinations were selected based on multi-analyte integration.
The study included patients with recurrent refractory metastatic epithelial malignancies with progression after ≥2 lines of systemic treatment. The primary endpoints were: quality of life (QoL), progression-free survival (PFS), and objective response rate (ORR).

93,9 %
QoL
Quality of life
90,5 %
PFS
Progression-free survival
42,9 %
ORR
Objective response rate

In 90.5% of patients, further cancer progression was effectively halted, while 42.9% experienced a significant reduction in the extent of cancer spread
No serious side effects or treatment-related deaths were reported
Most patients reported either stable or improved quality of life

Indications

Ineffectiveness of first-line therapy
Cancer recurrence
High-grade or metastatic cancer
Cancer with limited or no standard treatment options
Recently diagnosed, difficult-to-treat disease
Complex types of cancer, such as gastric, esophageal, pancreatic, gallbladder, GIST, and others
High risk of therapeutic failure

Different Diagnostic Solutions

Decided to take the Exacta!

Book your first consultation with a doctor

The doctor will inform you about the upcoming testing, answer any questions you may have, and then ask you to sign an informed consent form for the test. Then, the doctor will complete a special form (application) according to the requirements of Datar Cancer Genetics

Book a consultation

Where can I get tested?

Chisinau

21 N. Теstemițanu, street
Monday – Tuesday, 07:30 - 14:30 I Wednesday, 07:30 - 09:00

Laboratory Report

The test results provided in the laboratory report are intended for professional use only by qualified specialists, considering the
capabilities/limitations/characteristics of the test, the patient's current health status, clinical history, and diagnostic data

VIEW SAMPLE REPORTS

Exacta COMPREHENSIVE

Blood

Blood, Tissue

Blood, Tissue, Non-oncological drugs

Exacta BASIC

Blood

Blood, Tissue